Author

S Delalogue

Institutions: University of North Carolina at Chapel Hill, Mayo Clinic, Fondazione Michelangelo, University Hospital Schleswig-Holstein, Hospital Clínic de Barcelona, Dana-Farber Cancer Institute, New York University

Observed institutions: University of North Carolina at Chapel Hill, Mayo Clinic, Fondazione Michelangelo, University Hospital Schleswig-Holstein, Hospital Clínic de Barcelona, Dana-Farber Cancer Institute, New York University

OpenAlex ID: A5048419704

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

2019 · O Metzger, S Mandrekar, et al. · Cancer Research · 15

Works count: 1

Citation count: 15

H-index: 1

I10-index: 1